Chemotherapy-Induced Nausea And Vomiting Therapeutics Market

Future Market Insights

Key Insight

The chemotherapy-induced nausea and vomiting therapeutics market is projected to grow from USD 6.9 billion in 2025 to USD 13.0 billion by 2035, at a CAGR of 6.5%. Dopamine Antagonists will dominate with a 36.6% market share, while hospital pharmacy will lead the distribution channel segment with a 35.6% share.

October 08, 2025

Anurag Sharma

250 Pages

Cite this Report

Chemotherapy-Induced Nausea And Vomiting Therapeutics Market

https://www.futuremarketinsights.com/reports/chemotherapy-induced-nausea-and-vomiting-therapeutics-market

License

Buy Now

Summary ToC Companies

Key Players

AbbVie Inc. (Allergan PLC)
Camurus AB
GSK
Heron Therapeutics
Kyowa Kirin Co. Ltd
Merck KGaA
Novartis
Ono Pharmaceutical Co. Ltd
The Vanguard Group

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Chemotherapy-Induced Nausea And Vomiting Therapeutics Market

Key Players

Similar Industry Reports